author-photo

Barbara Pro

University of Texas MD Anderson Cancer Center
Northwestern University
Fox Chase Cancer Center

346

Papers

10285

Citations

Citation Trend

Filter By

Papers (346) Sort By

Journal Conference Others

A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides.

2021 Journal of Drugs in Dermatology
Show All
- Source
- Cite
- Save
Citations (2)
Phase I Study of Novel SYK Inhibitor TAK-659 in Combination with R-CHOP for Front-Line Treatment of High Risk Diffuse Large B-Cell Lymphoma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
MULTI‐CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE FOR PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA (PTCL)

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
T time: Emerging and new therapies for peripheral T-cell lymphoma

2021 Blood Reviews
- Alain Mina
- Barbara Pro
Show All
- Source
- Cite
- Save
Citations (0)
ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)